Get the Stockscreener App
7.055
4.01%
-0.295
After Hours:
7.08
0.025
+0.35%
Biocryst Pharmaceuticals Inc stock is traded at $7.055, with a volume of 4.07M.
It is down -4.01% in the last 24 hours and down -6.93% over the past month.
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.
See More
Previous Close:
$7.35
Open:
$7.38
24h Volume:
4.07M
Relative Volume:
2.02
Market Cap:
$1.49B
Revenue:
$331.41M
Net Income/Loss:
$-226.54M
P/E Ratio:
-5.644
EPS:
-1.25
Net Cash Flow:
$-97.31M
1W Performance:
-13.12%
1M Performance:
-6.93%
6M Performance:
+58.54%
1Y Performance:
+16.80%
1-Day Range:
$7.03
$7.4392
1-Week Range:
$6.845
$8.44
52-Week Range:
$4.03
$8.88
Biocryst Pharmaceuticals Inc Stock (BCRX) Company Profile
Name
Biocryst Pharmaceuticals Inc
Sector
Industry
Phone
919-859-1302
Address
4505 EMPEROR BOULEVARD, DURHAM, NC
Biocryst Pharmaceuticals Inc Stock (BCRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-18-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Aug-04-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-13-23 | Upgrade | BofA Securities | Neutral → Buy |
| Feb-22-23 | Upgrade | Needham | Hold → Buy |
| Nov-02-22 | Upgrade | Evercore ISI | In-line → Outperform |
| Aug-05-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Aug-05-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Apr-18-22 | Downgrade | Barclays | Overweight → Equal Weight |
| Apr-11-22 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-10-21 | Initiated | Oppenheimer | Outperform |
| Aug-06-21 | Downgrade | Jefferies | Buy → Hold |
| Aug-03-21 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-01-21 | Initiated | Cowen | Outperform |
| Sep-29-20 | Resumed | JP Morgan | Overweight |
| Jun-17-20 | Initiated | BTIG Research | Neutral |
| May-05-20 | Upgrade | Barclays | Equal Weight → Overweight |
| Nov-15-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| May-24-19 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-16-18 | Resumed | Piper Jaffray | Overweight |
| Aug-08-18 | Resumed | JP Morgan | Overweight |
| Jul-17-18 | Upgrade | BofA/Merrill | Underperform → Neutral |
| Jun-22-18 | Initiated | Seaport Global Securities | Neutral |
| Jan-02-18 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Dec-20-17 | Initiated | Barclays | Equal Weight |
| Sep-15-17 | Initiated | RBC Capital Mkts | Sector Perform |
| Sep-06-17 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-06-17 | Upgrade | Jefferies | Hold → Buy |
| Feb-16-17 | Initiated | Ladenburg Thalmann | Buy |
| Aug-12-16 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Aug-04-16 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Feb-09-16 | Reiterated | FBR Capital | Outperform |
| Feb-09-16 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-09-16 | Downgrade | Needham | Buy → Hold |
View All
Biocryst Pharmaceuticals Inc Stock (BCRX) Latest News
BioCryst Pharmaceuticals (NASDAQ:BCRX) Announces Earnings Results, Meets Estimates - MarketBeat
BioCryst Pharmaceuticals (NASDAQ:BCRX) Receives "Buy" Rating from Needham & Company LLC - MarketBeat
Barclays Forecasts Strong Price Appreciation for BioCryst Pharmaceuticals (NASDAQ:BCRX) Stock - MarketBeat
BCRXBioCryst Pharmaceuticals Inc Latest Stock News & Market Updates - StockTitan
BioCryst Announces Strong Q3 2024 Revenue Growth - Yahoo Finance
BioCryst Pharmaceuticals, Inc. Provides Financial Guidance for the Year 2024, Second Half of 2025 and Full Year of 2026 - Marketscreener.com
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
BioCryst Pharmaceuticals Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags - Simply Wall St
BioCryst Pharmaceuticals Inc (BCRX) Q3 2024 Earnings Call Highli - GuruFocus.com
Vanguard Group Inc's Strategic Acquisition in BioCryst Pharmaceu - GuruFocus.com
BioCryst Pharmaceuticals Inc (BCRX) Q3 2024 Earnings Call Highlights: Strong ORLADEYO Growth ... - Yahoo Finance
BioCryst Pharmaceuticals (BCRX) Reports Q3 Loss, Tops Revenue Estimates - MSN
Earnings call: BioCryst Pharmaceuticals reports strong Q3 growth - Investing.com
Earnings call: BioCryst Pharmaceuticals reports strong Q3 growth By Investing.com - Investing.com UK
Piper Sandler lifts BioCryst Pharma target to $21 on Q3 beat - Investing.com UK
BioCryst shares hold Buy rating, BofA sees entry point By Investing.com - Investing.com UK
BioCryst Pharmaceuticals (BCRX) Q3 2024 Earnings Call Transcript - AOL
BioCryst Pharmaceuticals (NASDAQ:BCRX) Shares Gap DownTime to Sell? - MarketBeat
BioCryst Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
BioCryst: Q3 Earnings Snapshot - The Washington Post
BioCryst Pharmaceuticals Q3 2024 Earnings: EPS Loss of $0.07, Re - GuruFocus.com
BioCryst Reports Third Quarter 2024 Financial Results and Provides Business Update - GlobeNewswire
BioCryst Pharmaceuticals Q3 2024 Earnings Preview - MSN
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Shares Bought by Rice Hall James & Associates LLC - MarketBeat
‘Breakthrough’ quarter for Island Pharmaceuticals - The Mercury
Island Pharmaceuticals enjoys big quarter - Courier Mail
Semanteon Capital Management LP Invests $1.14 Million in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - MarketBeat
BioCryst Pharmaceuticals (BCRX) Scheduled to Post Earnings on Monday - MarketBeat
When (BCRX) Moves Investors should Listen - Stock Traders Daily
How Much Upside is Left in BioCryst (BCRX)? Wall Street Analysts Think 79.5% - MSN
What's Going On With BioCryst Pharmaceuticals Stock? - MSN
BioCryst Presents New Real-World Evidence Showing High - GlobeNewswire
BioCryst Presents New Real-World Evidence Showing High Adherence and Persistence Rates with ORLADEYO® (berotralstat) - StockTitan
BioCryst Pharmaceuticals (NASDAQ:BCRX) Stock Price Up 4.7%Here's What Happened - MarketBeat
Plasma Protease C1-inhibitor Market Growing at 9.6% CAGR To Reach US$ 7.96 Billion From 2024 to 2032 - EIN News
BioCryst to Report Third Quarter 2024 Financial Results on November 4 - The Manila Times
BioCryst To Report Third Quarter 2024 Financial Results On November 4 - Barchart
State Street Corp's Strategic Reduction in BioCryst Pharmaceuticals Holdings - GuruFocus.com
Where are the Opportunities in (BCRX) - Stock Traders Daily
Brokerages Set BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) PT at $14.17 - MarketBeat
T-Cell Lymphoma Treatment Market 2031 Insights with Key Innovations Analysis |BioCryst Pharmaceuticals, Johnson & Johnso – IndiaPolitics.com - IndiaPolitics.com
BioCryst study shows ORLADEYO cuts healthcare use in HAE By Investing.com - Investing.com South Africa
BioCryst to Present New Real-World Evidence Showing Significant Reductions in Medical Visits and Hospitalizations After Starting ORLADEYO® (berotralstat) - The Manila Times
BioCryst to Present New Real-World Evidence Showing - GlobeNewswire
Plasma Protease C1 Inhibitor Market Size, Development Growth, - openPR
Inspire Investing LLC Boosts Stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - MarketBeat
The Manufacturers Life Insurance Company Grows Stock Position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - MarketBeat
Is BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) The Top Stock With Improving Technical Ratings According To Piper Sandler? - Yahoo Finance
Institutional investors may overlook BioCryst Pharmaceuticals, Inc.'s (NASDAQ:BCRX) recent US$62m market cap drop as long-term gains remain positive - Simply Wall St
BioCryst to present ORLADEYO data at ACAAI meeting - Investing.com India
BioCryst to present ORLADEYO data at ACAAI meeting By Investing.com - Investing.com Australia
Biocryst Pharmaceuticals Inc Stock (BCRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.02%
0.47%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):